BioNTech Enters ADC Field with US$1.6 B+ DualityBio Licensing Deal
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 4 (Table of Contents)
Published: 6 Apr-2023
DOI: 10.3833/pdr.v2023.i4.2778 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In yet another deal to diversify its portfolio, BioNTech has entered into a licensing and collaboration agreement with Duality Biologics to develop, manufacture and commercialise two antibody-drug conjugate (ADC) therapies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS